SCHEMBL18038973

SCHEMBL18038973

O=C(Cn1cc(S(=O)(=O)N2CCCC2)ccc1=O)c1ccc(-c2ccc(-c3cccc4ccccc34)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ ALDH1A1 P00352 6/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ NPSR1 Q6W5P4 3/20 0.46
▸ POLB P06746 3/20 0.46
▸ LMNA P02545 2/20 0.46
▸ PKM P14618 1/20 0.46
▸ GAA P10253 3/20 0.42
▸ MAPT P10636 3/20 0.42
▸ MAPK1 P28482 2/20 0.42
▸ TNF P01375 1/20 0.42
▸ NOD2 Q9HC29 1/20 0.42
▸ NOD1 Q9Y239 1/20 0.42
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ CA12 O43570 1/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ CA9 Q16790 1/20 0.41
▸ KDM4E B2RXH2 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18039005 0.99 L3MBTL1 (0.47) L3MBTL1ALDH1A1SMN1; SMN2NPSR1POLB
SCHEMBL18038946 0.93 L3MBTL1 (0.46) L3MBTL1ALDH1A1SMN1; SMN2NPSR1POLB
SCHEMBL21820002 0.87 L3MBTL1 (0.44) L3MBTL1ALDH1A1SMN1; SMN2NPSR1POLB
SCHEMBL18038959 0.87 L3MBTL1 (0.56) L3MBTL1ALDH1A1SMN1; SMN2NPSR1POLB
SCHEMBL18038989 0.87 L3MBTL1 (0.56) L3MBTL1ALDH1A1SMN1; SMN2NPSR1POLB
SCHEMBL18038954 0.87 L3MBTL1 (0.56) L3MBTL1ALDH1A1SMN1; SMN2NPSR1POLB
SCHEMBL18038944 0.86 AKR1C3 (0.51) L3MBTL1ALDH1A1SMN1; SMN2NPSR1POLB
SCHEMBL18038987 0.85 MCOLN3 (0.49) L3MBTL1ALDH1A1SMN1; SMN2NPSR1POLB
SCHEMBL18039003 0.85 MCOLN3 (0.49) L3MBTL1ALDH1A1SMN1; SMN2NPSR1POLB
SCHEMBL18038963 0.85 ALDH1A1 (0.48) L3MBTL1ALDH1A1SMN1; SMN2NPSR1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11311523-B2 Pyridinone compound and use thereof KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2022-04-26 — — US disclosed
EP-3692992-A1 METHOD OF SCREENING DOCK1-SELECTIVE INHIBITORS FOR CANCER TREATMENT Kyushu University National University Corporation (JP) 2020-08-12 — — EP disclosed
EP-3263133-B1 PYRIDINONE COMPOUND AND USE THEREOF UNIV KYUSHU NAT UNIV CORP (JP) 2020-04-01 — — EP disclosed
US-20200061039-A1 PYRIDINONE COMPOUND AND USE THEREOF KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2020-02-27 — — US disclosed
US-10406141-B2 Pyridinone compound and use thereof KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2019-09-10 — — US disclosed
US-20180028515-A1 PYRIDINONE COMPOUND AND USE THEREOF KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2018-02-01 — — US disclosed
EP-3263133-A1 PYRIDINONE COMPOUND AND USE THEREOF Kyushu University, National University Corporation (JP) 2018-01-03 — — EP disclosed
WO-2016136985-A1 PYRIDINONE COMPOUND AND USE THEREOF 国立大学法人九州大学 2016-09-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180028515-A1 PYRIDINONE COMPOUND AND USE THEREOF DOCK5, DOCK2, CIB1 L3MBTL1 2983/4885ALDH1A1 52/4885SMN1; SMN2 2842/4885
US-20200061039-A1 PYRIDINONE COMPOUND AND USE THEREOF DOCK5, DOCK2, CIB1 L3MBTL1 2940/4885ALDH1A1 49/4885SMN1; SMN2 2818/4885
US-10406141-B2 Pyridinone compound and use thereof DOCK5, DOCK2, CIB1 L3MBTL1 2983/4885ALDH1A1 52/4885SMN1; SMN2 2842/4885
US-11311523-B2 Pyridinone compound and use thereof DOCK5, DOCK2, CIB1 L3MBTL1 2940/4885ALDH1A1 49/4885SMN1; SMN2 2818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback